Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Cytosorbents Stories

2014-03-13 08:27:59

MONMOUTH JUNCTION, N.J., March 13, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled: "SIRS and SEPSIS - New Therapy with CytoSorb®" at the 34(th) International Symposium on Intensive Care and Emergency Medicine (ISICEM 2014) in Brussels, Belgium next week. The program is scheduled for...

2013-05-29 08:32:06

MONMOUTH JUNCTION, N.J., May 29, 2013 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, was recently featured in the article "Blood Purification Device for ICU Patients Seeks to Treat Root Cause of Sepsis" on May 24, 2013 in MedCity News. Highlights from the MedCity News Article: The cost of treating sepsis was $14.6 billion in 2008, according to the Centers for...

2013-03-13 08:33:56

MONMOUTH JUNCTION, N.J., March 13, 2013 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it will exhibit its European Union approved CytoSorb® cytokine reduction technology at the 33(rd) International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium from March 19-22, 2013. In addition, Dr. Dirk Schadler, from the University Hospital,...

2013-01-29 08:31:38

MONMOUTH JUNCTION, N.J., Jan. 29, 2013 /PRNewswire/ -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced today that, as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority, it has received $391,562 from the sale of its prior unused net operating loss carryovers. These funds are non-dilutive to shareholders and...

2013-01-04 08:23:21

MONMOUTH JUNCTION, N.J., Jan. 4, 2013 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that Dr. Phillip Chan, Chief Executive Officer, will present at the OneMedForum 2013 Emerging Company Finance Conference on Tuesday, January 8, 2013 in San Francisco at the Sir Francis Drake Hotel. Dr. Chan's presentation will take place at 10:40AM PST in the Windsor Room with a breakout session...

2012-11-16 08:23:59

MONMOUTH JUNCTION, N.J., Nov. 16, 2012 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses such as sepsis, trauma, and burn injury, announced today that due to a loss of power for an extended period of time caused by Superstorm Sandy, the Company has been granted additional time by the Securities and Exchange Commission to file its Form 10-Q for the quarter ended September 30, 2012. Although the...

2012-09-07 02:24:21

MONMOUTH JUNCTION, N.J., Sept. 7, 2012 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to modulate the immune system, reduce severe inflammation, and fight organ failure caused by life-threatening illnesses such as sepsis, announced that it has become a member and sponsor of the Germany Sepsis Society and a sponsor of the Sepsis Heroes Evening, hosted by the Sepsis Alliance, in honor of the first World Sepsis Day on...